Showing results (21-30 of 66) with videos related to
Sort By:
Pageof 7
Journal of Medicinal Chemistry|September 30, 2005
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinaseChunjian Liu, Stephen T Wrobleski, James Lin, et al.Bioorganic & Medicinal Chemistry Letters|November 20, 2010
Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritisAlaric J Dyckman, Charles M Langevine, Claude Quesnelle, et al.Bioorganic & Medicinal Chemistry Letters|April 2, 2014
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseasesQing Shi, Andrew Tebben, Alaric J Dyckman, et al.Journal of Medicinal Chemistry|April 24, 2015
Improving the pharmacokinetic and CYP inhibition profiles of azaxanthene-based glucocorticoid receptor modulators-identification of (S)-5-(2-(9-fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341)Michael G Yang, T G Murali Dhar, Zili Xiao, et al.Journal of Medicinal Chemistry|December 13, 2006
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitorJagabandhu Das, Ping Chen, Derek Norris, et al.Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.Bioorganic & Medicinal Chemistry Letters|May 10, 2006
Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitorsJagabandhu Das, Joseph A Furch, Chunjian Liu, et al.Bioorganic & Medicinal Chemistry Letters|March 28, 2008
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitorsStephen T Wrobleski, Shuqun Lin, John Hynes, et al.The Journal of Pharmacology and Experimental Therapeutics|August 5, 2009
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritisKathleen M Gillooly, Mark A Pattoli, Tracy L Taylor, et al.ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P1) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.Pageof 7